BRCA1 and cancer: Reactivation of HR through secondary mutations or epigenetic regulation of BRCA1/2 is frequently identified and has been found in patients with ovarian [62–65], breast [63, 64, 66], pancreatic [67] and prostate [68, 69] cancer with PARPi-resistant disease.